Oncolytic viruses induce their anticancer activity through several mechanisms such as a preferential replication in dividing tumor cells until apoptosis and cell death, tumor cell specificity, the targeting of dysfunction pathway (such as TP53), the induction of specific and non-specific anti-tumor immunity and last suppression of cancer-stem cells [102]. This evidence concerns the gene TP53 and cancer.